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Abstract
Background: Matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) are increased in the brain
after experimental ischemic stroke in rats. These two proteases are involved with the degradation
of the basal lamina and loss of stability of the blood brain barrier that occurs after ischemia and that
is associated with thrombolytic therapy in ischemic stroke. Minocycline is a lipophilic tetracycline
and is neuroprotective in several models of brain injury. Minocycline inhibits inflammation,
apoptosis and extracellular matrix degradation. In this study we investigated whether delayed
minocycline inhibits brain MMPs activated by ischemia in a model of temporary occlusion in Wistar
rats.
Results: Both MMP-2 and MMP-9 were elevated in the ischemic tissue as compared to the contra-
lateral hemisphere after 3 hours occlusion and 21 hours survival (p < 0.0001 for MMP-9).
Intraperitoneal minocycline at 45 mg/kg concentration twice a day (first dose immediately after the
onset of reperfusion) significantly reduced gelatinolytic activity of ischemia-elevated MMP-2 and
MMP-9 (p < 0.0003). Treatment also reduced protein concentration of both enzymes (p < 0.038
for MMP-9 and p < 0.018 for MMP-2). In vitro incubation of minocycline in concentrations as low
as 0.1 µg/ml with recombinant MMP-2 and MMP-9 impaired enzymatic activity and MMP-9 was
more sensitive at lower minocycline concentrations (p < 0.05).
Conclusion: Minocycline inhibits enzymatic activity of gelatin proteases activated by ischemia after
experimental stroke and is likely to be selective for MMP-9 at low doses. Minocycline is a potential
new therapeutic agent to acute treatment of ischemic stroke.
Background
Matrix metalloproteases (MMPs) are a family of zinc
dependent proteases responsible for the extracellular
matrix turnover and degradation of bioactive proteins. In
cerebral ischemia, MMPs 2 and 9, also designated as gela-
tinases A (72 kDa) and B (92 kDa) have been identified to
mediate the degradation of the basal lamina [1,2] and
hemorrhagic transformation [3]. MMPs 2 and 9 have been
shown to be elevated a few hours after ischemia [4] and to
maintain increased activity for days after the onset [2,5].
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The inhibition of these enzymes by specific class inhibi-
tors reverts breakdown of laminin [6] and prevents
increased barrier permeability, edema, and hemorrhage
after ischemic stroke [7-9]. The development of MMP
inhibitors as therapeutic agents has been limited by their
poor solubility.
Minocycline is a commonly used semi-synthetic tetracy-
cline with anti-inflammatory and anti-apoptotic proper-
ties [10,11]. Minocycline interferes with MMP activity
[12,13] and has been shown to be neuroprotective in cer-
ebral ischemia [14] and in other models of brain injury
[15,16].
In this study we investigated whether minocycline pre-
vents ischemia-induced MMP activation in a temporary
model of temporary focal cerebral ischemia in rats, and
explored the dose-response relationship and possible spe-
cificity of in vitro MMP-inhibition by this drug. Because
MMP-2 and MMP-9 have distinct mechanisms of activa-
tion and different roles after stroke, the potential selectiv-
ity of minocycline for either enzyme should be
determined. Furthermore, MMP inhibition may be the
central mechanism through which minocycline provides
neurovascular protection [17]. There are currently no
drugs marketed specifically for their ability to inhibit sys-
temic MMPs. Minocycline could represent a new clinical
approach to inhibiting acute MMP activation, reducing
the risk of development of hemorrhage and protecting the
patient from further damage after acute ischemic stroke.
Results
MMP activity after ischemic stroke
The 3 hour ischemia followed by 21 hour survival after
reperfusion caused increased activity of MMP-2 and
MMP-9 in the ischemic hemisphere (Fig. 1) as compared
to the contra-lateral hemisphere (n = 8, p < 0.0001 for
MMP-9, MMP-2 activity was increased, but not signifi-
cantly). The densitometric analysis revealed also that
intra-peritoneal minocycline 45 mg/kg treatment twice a
day (first dose immediately after reperfusion), signifi-
cantly reduced the ischemia-induced increments in both
MMP-2 and MMP-9 active gelatinolytic forms (n = 6 for
control and 8 for treated animals) (p < 0.0003) (Fig. 2).
The same treatment regimen with intra-peritoneal minoc-
ycline also significantly reduced the ischemia-induced
increase in MMP total protein concentration (Fig. 3) (n =
6 for PBS and 8 for minocycline treated groups, p < 0.038
for MMP-9 and p < 0.018 for MMP-2).
Neurological evaluation
All animals had a significant deficit (scored 3 points in the
Bederson Scale) prior to reperfusion, demonstrating suc-
cessful MCAO. The neurological scores did not show a sig-
nificant difference between the treatment and control
groups. The scale shows a high variability between ani-
mals and a much higher sample size is required to detect
a significant difference.
In vitro MMP inhibition by minocycline
The densitometric analysis revealed that minocycline at
0.1 µg/ml, 0.5 µg/ml, 1 µg/ml, 10 µg/ml, 50 µg/ml, 100
µg/ml, 500 µg/ml and 1000 µg/ml concentrations signifi-
cantly inhibited the activity of recombinant MMP-2 and
recombinant MMP-9 as compared to the control enzy-
matic activity. The inhibitory effect of minocycline in both
enzymes was similar or slightly greater than the positive
control EDTA in 1 µg/ml concentration (not shown).
There was a significant interaction between the two pro-
teases and minocycline drug concentration such that, at
concentrations of 100 ug/ml and below, the percent inhi-
bition is significantly higher for MMP-9 (p < 0.05) (Fig 4).
Discussion
This study demonstrated for the first time that delayed
treatment with minocycline inhibits MMPs that are ele-
vated after temporary experimental cerebral ischemia. In
addition, this inhibitory effect is present over a wide range
of clinically relevant and safe concentrations of minocy-
cline. In fact, the minocycline concentration expected in
the brain after a normal dose of 200 mg in humans (3 mg/
kg in rodents), is equivalent to 0.5–1 µg/ml [18] and is
higher than the lowest in vitro doses tested. Furthermore,
our results reinforce previous findings that minocycline is
a potent inhibitor of MMP-9 in vivo [19] and in vitro [13]
and suggests a sensitivity of this enzyme for the drug when
compared to MMP-2. Our drug dosing regimen was based
on previous studies demonstrating therapeutic efficacy of
intra-peritoneal minocycline 45 mg/kg in experimental
stroke [14,18] and to achieve a constant plasma concen-
tration since the timing of MMP activation spike has not
yet been identified either in humans or in rodents. Intra-
peritoneal delivery of minocycline in our model of stroke
also insures that regardless of differences in the pharma-
cokinetics of this drug in rodents, the drug will be present
whenever the activation of the MMP enzymes occurs, as
the delivery of the drug is slow and constant.
Minocycline has been shown to be neuroprotective
[14,20,21]. One common pathophysiological mechanism
of models of brain ischemic damage is the dysregulation
of the proteolytic cascade at the level of the endothelial
and microglial cells. Interference of this cascade by mino-
cycline might be the central pathway for these neurovas-
cular protective properties of decreasing tissue injury and
also providing functional recovery. Ischemic stroke acti-
vates a complex cascade of events [22]. The first tissue
damage occurs as early as a few minutes after the occlu-
sion. Within hours after stroke onset, endothelial and
inflammatory cells respond to ischemia releasing pro-BMC Neuroscience 2006, 7:56 http://www.biomedcentral.com/1471-2202/7/56
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teases MMP-2 and MMP-9 that culminate in degradation
of the basal lamina and ultimate weakening of the blood
brain barrier [23]. The subsequent events are leakage of
leukocytes into the parenchyma, and brain edema fol-
lowed by neuronal death that occurs in the later hours of
ischemia. Since MMP-2 and MMP-9 are believed to be
largely responsible for the degradation of the blood brain
barrier and also involved in the signaling of neuronal cell
death [24,25], the inhibition of the proteolytic cascade is
a logical target for several models of brain injury that
involve matrix degradation and vascular instability [26].
Our studies point to an apparent selectivity of minocy-
cline for MMP-9 with low dose minocycline. This could
reflect either a time profile difference between the activa-
tion of the two enzymes, the pathway minocycline inter-
feres, or a chemical selectivity for MMP-9. Among the
main differences between their molecular pathways,
MMP-2 is constitutively expressed, while MMP-9 can be
stimulated at the level of gene activation by multiple stim-
uli including ischemia. Both enzymes are expressed as
pro-forms and after they are secreted they require chemi-
cal or proteolytic activation to become functional [27]. In
endothelial brain cells, little is known about the presence
and regulation of the different MMPs [28,29]. Further
studies are necessary to determine the mechanisms of acti-
vation of MMPs in the brain after ischemia and the mech-
anism by which minocycline decreases MMP activity.
Minocycline has in its chemical structure an active bind-
ing site that confers the ability to chelate divalent ions.
Our in vitro studies confirm that minocycline is able to
inhibit gelatin digestion by MMPs by interacting with
these enzymes. MMPs require zinc in their active site for
functional activity and removal of the zinc results in
Intra-peritoneal minocycline 45 mg/kg treatment twice a day  (first dose immediately after reperfusion), significantly  reduced the ischemia-induced increase in MMP-2 and MMP-9  gelatinolytic activities (represented by the active form bands;  67 and 86 kDa respectively) Figure 2
Intra-peritoneal minocycline 45 mg/kg treatment twice a day 
(first dose immediately after reperfusion), significantly 
reduced the ischemia-induced increase in MMP-2 and MMP-9 
gelatinolytic activities (represented by the active form bands; 
67 and 86 kDa respectively). Sample sizes: PBS n = 6; Minoc-
ycline n = 8 (p < 0.0003). Each band represents one different 
replicate sample.
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The ischemic hemisphere has increased MMP-9 (significant increase) and MMP-2 activity as compared to the contra-lateral non  ischemic control hemisphere in non-treated animals Figure 1
The ischemic hemisphere has increased MMP-9 (significant increase) and MMP-2 activity as compared to the contra-lateral non 
ischemic control hemisphere in non-treated animals. Sample sizes: n = 8 for both PBS and minocycline treated groups (p < 
0.0001 for MMP-9 increase). Each band represents one different replicate sample. Molecular weights were determined with the 
use of pre-stained protein standards.
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change of conformation and inactivation of the enzyme.
Tetracyclines have been shown to inhibit collagenolysis
[30,31] and inhibit MMP-9 activity [32]. Previous studies,
however, have shown that multiple tetracyclines can
inhibit collagenase MMPs via down-regulation of gene
expression in a cellular model of rheumatoid arthritis
using cultured chondrocytes [33] and that pre-treatment
with minocycline down-regulates pro-MMP expression
after permanent cerebral ischemia [17]. Furthermore,
because minocycline has been shown to be neuroprotec-
tive in different models of brain injury, it is likely to act by
multiple mechanisms, with MMP inhibition being a cen-
tral link for its anti-inflammatory and anti-apoptotic
properties in the ischemic cascade and reperfusion. Our
studies are pioneer in investigating the ability of minocy-
cline to decrease MMP activity in the setting of a tempo-
rary model of stroke, and with treatment occurring post
reperfusion. Increase in MMP activity and its conse-
quences are relevant in stroke from the standpoint of
ischemic damage itself and also from the standpoint of
delayed reperfusion damage alone.
In order to determine the clinical relevance of these find-
ings for acute stroke treatment, the next step is to deter-
mine if the MMP inhibition by minocycline in a model of
temporary occlusion will result in decreased blood brain
barrier degradation and decreased hemorrhage formation.
In addition, the vascular protection properties of minocy-
cline should also be studied for ischemic stroke after treat-
ment with tissue plasminogen activator (tPA). tPA is
currently the only available acute treatment for ischemic
stroke patients but its application is limited due to the
increased risk of serious intracerebral bleeding [34].
Because tPA is an extracellular protease and is not highly
specific for plasminogen cleavage, reperfusion with tPA
might amplify the MMP damage in the brain as has been
previously speculated [35,36] and concurrent administra-
tion of minocycline with tPA or other reperfusion agents
might be a potential approach for reestablishing blood
Minocycline concentrations ranging within 0.1 and 1000 µg/ ml inhibits the activity of 0.05 ng recombinant human MMP-2  and MMP-9 as compared to the control enzymatic activity Figure 4
Minocycline concentrations ranging within 0.1 and 1000 µg/
ml inhibits the activity of 0.05 ng recombinant human MMP-2 
and MMP-9 as compared to the control enzymatic activity. At 
low concentrations, MMP-9 inhibition is greater than that of 
MMP-2 (p < 0.05).
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Intra-peritoneal minocycline 45 mg/kg treatment twice a day (first dose immediately after reperfusion), significantly reduced  the ischemia-induced increase in MMP-2 and MMP-9 total protein concentrations as compared to PBS treated control animals Figure 3
Intra-peritoneal minocycline 45 mg/kg treatment twice a day (first dose immediately after reperfusion), significantly reduced 
the ischemia-induced increase in MMP-2 and MMP-9 total protein concentrations as compared to PBS treated control animals. 
Sample sizes: PBS n = 6; Minocycline n = 6 (p < 0.038 for MMP-9 and p < 0.018 for MMP-2). Each band represents one different 
replicate sample.
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flow without compromising the vasculature. These studies
are currently ongoing.
Conclusion
Our studies provide evidence that the inhibition of MMP
enzymatic activity can be achieved with intraperitoneal
treatment of minocycline after experimental ischemic
stroke. MMP inhibition is likely a mechanism through
which minocycline is neuroprotective in stroke. Further-
more, the in vitro inhibitory effect of minocycline is
observed at very low therapeutic concentrations with
MMP-9 being more. Because thrombolytic agents exacer-
bate the proteolytic cascade, minocycline raises optimism
for the acute treatment of ischemic stroke patients. Mino-
cycline is a candidate neuroprotective agent to be used in
combination with tPA.
Methods
Drug preparation and regimen
Minocycline powder was purchased from Sigma Aldrich
CO., Saint Louis, MO. The drug was prepared fresh one
hour prior to administration by dissolution in phosphate
buffered saline (PBS) pH 7.4 (Fisher Scientific, Pittsburgh,
PA). The preparation tube was covered with aluminum
foil and protected from light. Minocycline was adminis-
tered intraperitoneally to animals in two doses of 45 mg/
kg, the first one being 5 minutes after the onset of reper-
fusion and the second one 12 hours later. This dosing reg-
imen was based on previous studies [14,18]. The injection
was 9 ml/kg. Animals were randomized between the
minocycline treated group and the PBS treated group and
received equivalent injection volumes.
Animal procedures and experimental stroke
The Institutional Animal Care and Use Committee
(IACUC) of the Veterans Affairs Medical Center approved
the protocol. Male Wistar rats purchased from Charles
River Laboratory (Wilmington, MA) were used. Animals
used were within a range of 270–300 g of body weight.
Cerebral ischemia was induced by intraluminal suture
occlusion of the MCA [37]. A 20 mm 3.0 nylon monofil-
ament with round tip was inserted through the right inter-
nal carotid artery up to the origin of the MCA. After 3
hours of ischemia the animals were reperfused by remov-
ing the suture. The animals were anesthetized with iso-
fluorane inhalation in a glass chamber prior to stroke
procedure and reperfusion. The anesthesia was kept by
2% isofluorane during surgery. Body temperature was
maintained with heating pad during surgery and reper-
fusion. The animals were evaluated neurologically and for
motor ability using the Bederson Scale [38] prior to reper-
fusion and sacrifice. Prior to sacrifice, which occurred 24
hours after stroke, the animals were anesthetized with a
cocktail of ketamine (45 mg/kg) and xylazine (15 mg/kg)
via intramuscular injection. The animals were then per-
fused with ice cold PBS, sacrificed and the brains were
extracted.
Tissue processing, immunoblotting and gelatin 
zymography
After extraction, the brain was washed with PBS and
placed in a coronal matrix. The olfactory bulb and the first
2 mm-thick slice of the anterior brain were discarded.
Four consecutive 2 mm slices corresponding to the major
infarcted area and the contra-lateral hemisphere were sep-
arated as a block. The ischemic and non ischemic hemi-
spheres were then separated, placed in cryotubes and flash
frozen in liquid nitrogen. The tubes were stored in a -
80°C freezer until homogenization. The samples were
homogenized in 450 µL of cold working buffer containing
50 mM Tris-HCl (pH 7.5), 75 mM NaCl, and 1 mM PMSF
as described by Heo and collaborators [3]. The tissue was
processed with a homogenizer for 10 minutes and centri-
fuged at 4°C for 20 minutes at 13000 rpm. The superna-
tants were separated, frozen and kept at -80°C until use.
The total protein concentration was assessed by the Brad-
ford method.
On the day of the experiment, the volume equivalent to
50 µg of total protein was loaded into fresh made 10%
polyacrylamide gels (Immunoblotting) or gelatin zymog-
raphy gels. For the zymography experiments, the gels were
electrophoretically separated under non reducing condi-
tions and 100 V. After electrophoresis the zymogram gels
were washed in 125 ml 2.5% Triton twice for 20 minutes.
The gels were then incubated in activation buffer (Zymo-
gram Development Buffer, Bio-Rad, Hercules, CA) for 20
hours at 37°C. The next day, the gels were stained with
Coomassie Blue R-250 Staining Solution (Bio-Rad) for 3
hours and destained for 25 minutes with Destain Solution
(Bio-Rad). The gelatinolytic activity of the samples was
assessed by densitometric analysis (Gel-Pro v 3.1, Media
Cybernetics, Carlsbad, CA) of the bands as a relative com-
parison to a standard band of recombinant enzyme. To
minimize inter-gel variability, all gels had a control lane
loaded with 0.5 ng recombinant enzyme, which was used
as a standard optical density and enzyme amount (in ng).
The lytic bands identified in the zymogram gels were sub-
jected to molecular weight identification with the use of
pre-stained standard protein marker (Bio-Rad). For the
immunoblotting experiments, the gels were transferred
into nitrocellulose membranes for one hour. Membranes
were blocked with blotting grade blocker non- fat dry milk
(Bio-Rad). After washing with 0.1% tween 20- tris- buff-
ered saline (TTBS), the membranes were incubated with
either anti MMP-2 human (mouse) monoclonal antibody
(Oncogene Research Products) or anti MMP-9 mono-
clonal mouse antibody overnight at 4°C. Membranes
were washed again in TTBS, incubated with secondary
antibody (goat anti-mouse IgG, horseradish peroxidaseBMC Neuroscience 2006, 7:56 http://www.biomedcentral.com/1471-2202/7/56
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conjugated antibody, Calbiochem) for one hour and
finally developed with horseradish peroxidase develop-
ment solution (ECL advance detection kit, Amersham).
The membranes were exposed to autoradiography films
(Hyblot CL, Denville Scientific Inc.). The density of the
sample bands for the immunoblots and zymograms were
expressed as maximal optical density relative to the stand-
ard band.
In vitro MMP inhibition
The ability of minocycline to inhibit MMPs was tested by
a direct, cell free in vitro system, in which minocycline was
allowed to incubate at room temperature with recom-
binant active MMP-2 and MMP-9 (Oncogene, EMD Bio-
sciences, La Jolla, CA). Each enzyme was incubated
separately. 0.05 nanogram of recombinant enzyme
(1:10,000 dilution from the 5 µg/50 µl commercial stock)
was incubated with a range of clinically relevant concen-
trations: 0.1, 0.5, 1, 10, 50, 100, 500 and 1000 µg/ml of
minocycline prepared in deionized purified water. Two
control samples were used: the negative control in which
the enzyme was incubated with no drug, and the positive
control in which the enzyme was incubated with 10 µg/ml
EDTA. The samples were incubated for 2 hours and sepa-
rated on 10% zymogram gels as described above. The gels
were allowed to run in 100 V under non- reducing condi-
tions. After electrophoresis, the gels were washed twice
with 2.5 % Triton for 20 minutes each cycle. They were
then incubated for 20 hours with Zymogram Develop-
ment Buffer at 37°C. The gels were stained with Coomas-
sie Blue R-250 (Bio-Rad) for 3 hours and destained with
Destain Solution (Bio-Rad) for 25 minutes. The gelatino-
lytic bands were analyzed with densitometry (GelPro).
Statistics
A 2 MMP type (MMP-2 and MMP-9) by 2 group, (saline
or minocycline), analysis of variance (ANOVA) on the
ranks of the enzyme activity was used to determine the
differences in MMP activity, treatment group and their
interaction. A 2 MMP type (MMP-2 or MMP-9) by 6 con-
centrations (minocycline 0.1 µg/ml, minocycline 0.5 µg/
ml, minocycline 1 µg/ml, minocycline 100 µg/ml, mino-
cycline 500 µg/ml, and minocycline 1000 µg/ml) ANOVA
was used to determine differences in percent inhibition
for MMP type, minocycline concentration, and their inter-
action. A Tukey's test was used to adjust for post-hoc mul-
tiple comparisons. Statistical significance was determined
at p < 0.05 and SAS 9.1.3 was used for all analyses.
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